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Abstract
Medulloblastomas are the most common types of pediatric brain
tumors, that start in the cerebellum. They represent approximately 20% of
pediatric brain tumors, with an average age of diagnosis between 5 and 9
years old1. Surgery followed by radiation, and chemotherapy is the standard
treatment, however, it can be ineffective due to the location of the tumor and
the age of the patient. Thus, patients would benefit from non-toxic, targeted
therapeutics.
AXL, a receptor tyrosine kinase, is overexpressed in many types of
cancers and associated with poor patient survival. AXL is activated by its
ligand, Gas6. AXL/Gas6 signaling pathway has been shown to enhance
proliferation, invasion, metastasis, and drug resistance2.
Aptamers
are
synthetic,
single-stranded
RNA or
DNA
oligonucleotides that selectively bind their target proteins with high affinity.
Aptamers are considered chemical antibodies with the advantage to be
non-immunogenic and easy tumor penetration due to their small size.
The lower survival in patients expressing high levels of AXL makes it
a potentially viable therapeutic target in the treatment of brain cancer.
Additionally, the enhanced stability of the GLB-A04 aptamer and strong
binding to AXL have been shown to inhibit AXL in vivo. Here, although we
find no difference in cell viability or apoptotic protein expression,
experiments need to be repeated with higher concentrations of aptamer and
longer treatment times.
Here, we demonstrate that overexpression of AXL in GBM patients is
associated with poor survival. We then tested the ability of a highly modified
DNA aptamer, targeting AXL to inhibit phospho-AXL and produce effects
apoptosis by Western Blot and Annexin V/PI flow cytometry analysis. Thus,
aptamer-induced inhibition of phospho-AXL may be a viable therapeutic
target. Results obtained so far by us provide the strongest evidence and lay
the foundation for the next stage of development to advance towards the
translation of the aptamer candidates and companion biomarkers to the
clinic.

Introduction

Treatment with GLB-A04 fails to impact cell
viability in Annexin V/PI Flow Cytometry

• AXL has been identified as an important driver of mesenchymal and stemlike phenotype in diffuse pontine glioma (DIPG)
• Our group has generated a new molecule DNA aptamer targeting phosphoAXL with better features, more stable and higher activity, and bioavailability.
• Here, we examined the effect of the modified DNA aptamer GLB-A04 on two
medulloblastoma cell lines expressing high levels of AXL. DAOY and UW426
cells were treated with the DNA aptamer GLB-A04 and the effects on viability
and apoptosis were assessed.

Hypothesis
Targeting AXL leads to anti-tumor activity in medulloblastoma cell lines.

Objectives
• To determine the expression of AXL in medulloblastoma cell lines and
examine the effect on survivability.
• To determine the ability of GLB-A04 to inhibit phospho-AXL in
medulloblastoma cell lines.
• To examine the effects of GLB-A04 to induce apoptosis.

Results

Axl expression is correlated with poor survival, is
highly expressed in brain tumor and
medulloblastoma cell lines, and Axl activation is
inhibited by GLB-A04
Figure 4. Cells were incubated with varying concentration of GLB-A04 or
scramble aptamer for 72 hours and then collected, labeled with Annexin V
and PI and visualized via flow cytometry. No difference in viability or apoptotic
cell count was found between any of the concentrations of GLB-A04 and the
scramble control.

Conclusion
• AXL is highly expressed in medulloblastoma cell lines and
associated with poor patient survival.
• The GLB-A04 modified DNA aptamer downmodulated phosphoAXL in vitro.
• GLB-A04 modified DNA aptamer does not induce in vitro apoptosis
at the concentrations and times tested in the medulloblastoma cell
lines.

GLB-A04 Preliminary Data
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Methods

Figure 2. (A) High expression of AXL is associated with lower survival in brain
tumor patients (Center for Cancer Research, BioDiscovery Portal). (B) Axl is
overexpressed in brain tumors compared to normal tissue5. CCLE data6 (C)
and western blot analysis (D) indicate high expression of Axl in DAOY and
uw426 cell lines. (E) Gas6-stimulated (200ng/mL) medulloblastoma cell line
was treated with 400nM GLB-A04 and scramble aptamers to determine p-Axl
expression.

Treatment with GLB-A04 does not impact
expression of apoptotic proteins in DAOY and
uw426 cell lines

Cell lines : DAOY and uw426 cell lines were maintained in highglucose DMEM supplemented with 10% FBS and 1% penicillin. Cell
lines were maintained at 37ºC with 5% CO2 and 95% air.
Western Blotting: Cells were lysed in RIPA buffer with protease and
phosphatase inhibitors. Protein was quantified using BCA analysis
and samples were run on 4-15% polyacrylamide SDS gel. Protein
was transferred to PVDF membrane and blocked for 30min in 6%
milk. Antibodies were prepared in 5% milk and incubated for 48hr (pAxl) or overnight. Secondary antibodies were prepared in 5% milk
and incubated overnight (p-AXL) or for 90min. Bound antibodies
were visualized using ECL lighting reagents.
Flow Cytometry: Apoptosis assay was carried out using FITC
Annexin V Apoptosis detection kit (BD Pharmingen). Cells were
treated with GLB-A04 at varying concentrations for 96 or 120 hours.
Cells were then collected, washed with PBS, and treated with 4µL of
Annexin V and propidium iodide. After 10min incubation in the dark,
samples analyzed by flow cytometry.
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